Getting SINUVA to treat
nasal polyps

Getting SINUVA to treat
nasal polyps

Getting SINUVA to treat
nasal polyps

The SINUVA Sinus Implant is administered in your doctor’s office. Ask your doctor if SINUVA is right for you.

Download a brochure about SINUVA to help start a discussion with your doctor

Is SINUVA covered by insurance?

Insurance coverage varies by plan. It is important to check with your insurance payor to see if SINUVA is covered under your policy.

Will I need to pick SINUVA up from my local pharmacy?

After approval by your insurance, SINUVA is sent directly to your doctor’s office. Your doctor will then place the implant to treat your nasal polyps.

How should I talk to my doctor about SINUVA?

Your doctor will always be evaluating your condition for the right treatment option. Explore if SINUVA is right for you by expressing your desire for an alternative to surgery and current treatment options. Here are a few questions you can use to get the conversation started.

1. I’ve read about SINUVA. Do you think it’s right for me?

2. I don’t want any more surgery. What are my other options?

3. Can SINUVA help shrink my nasal polyps?

4. What are the risks of SINUVA?

By asking questions and starting a conversation, you’ll be helping your doctor plan the right treatment for you.

Stay Up-to-Date on SINUVA

Sign up below for the latest information about the SINUVA Sinus Implant.

INDICATION

SINUVA™ Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.

IMPORTANT SAFETY INFORMATION

Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids. If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

SINUVA is made from bioabsorbable polymers designed to soften over time. As the implant softens and polyps decrease, the implant may be expelled out of the nose on its own or with actions such as sneezing or forceful nose blowing. The implant can be removed 90 days after placement or earlier at the physician’s discretion. Repeat administration of SINUVA has not been studied.

As with other endoscopic sinus procedures, there are risks associated with the insertion or removal of SINUVA. SINUVA should be inserted by physicians trained in otolaryngology.

The nasal mucosa adjacent to the SINUVA Sinus Implant should be monitored for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid the use of SINUVA in patients with nasal ulcers or trauma.

The most common adverse reactions observed in clinical studies were bronchitis, nasopharyngitis, otitis media, headache, presyncope, asthma, and epistaxis.

Patients experiencing excessive nasal bleeding, symptoms of infection or symptoms suggesting that the implant has moved, such as irritation or a choking sensation in the back of the throat, should immediately contact a healthcare professional.

Close monitoring is recommended if patients have a change of vision or a history of increased intraocular pressure, glaucoma and/or cataracts.

You may report side effects to your physician or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . You may also report side effects to Intersect ENT at 1-866-531-6004.

RX Only. For important risk and use information about SINUVA, please see Full Prescribing Information.

Reference: SINUVA Prescribing Information, Intersect ENT. December 2017.

IMPORTANT SAFETY INFORMATION

Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids. If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal. Continue Reading

IMPORTANT SAFETY INFORMATION

Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Continue Reading

Start typing and press Enter to search